-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer
-
2023-507274-40-00
3
2021-04-22
Myelofibrosis
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-509120-17-00
5
2021-04-12
Myelofibrosis
-
2023-509405-77-00
5
2021-02-16
Colorectal cancer (BRAF V600E-mutant mCRC)
-
2022-501645-70-00
5
2020-11-25
Crohns Disease
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2023-504998-20-00
5
2020-09-18
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2023-508962-14-00
5
2020-06-18
Relapsed/Refractory Multiple Myeloma
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2022-502498-40-00
5
2019-07-26
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibr
-
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
-
2023-509349-11-00
5
2019-03-22
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
-
2023-506994-36-00
5
2018-10-11
Ulcerative Colitis
-
2023-506399-28-00
5
2017-11-08
Crohn's Disease
-
2022-501017-31-00
5
2016-05-10
Rheumatoid arthritis
-
2023-507705-34-00
5
2025-08-29
Moderate to Severe Active Ulcerative Colitis
-
2024-510826-16-00
5
2025-04-07
Rheumatoid Arthritis
-
2024-515615-22-00
4
2025-04-02
Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to
-
2024-514981-37-00
4
2024-12-05
Rheumatoid Arthritis
-
2024-511057-22-00
5
2024-12-04
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
-
2023-507680-19-00
4
2024-11-28
Sjögren’s Syndrome
-
2024-513104-34-00
4
2024-11-25
Major Depressive Disorder